Mizuho raised the firm’s price target on Avalo Therapeutics (AVTX) to $45 from $39 and keeps an Outperform rating on the shares post the Q1 report. The company continues to guide toward advancing abdakibart in hidradenitis suppurativa into registrational development, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTX:
- Avalo Therapeutics price target lowered to $35 from $40 at H.C. Wainwright
- Avalo Therapeutics price target lowered to $55 from $62 at Citizens
- Avalo Therapeutics Urges Investors to Heed Form 10-Q Risk Factors Amid Ongoing Uncertainty
- Avalo Therapeutics reports Q1 EPS (98c), consensus ($1.01)
- Avalo Therapeutics price target raised to $60 from $48 at Piper Sandler